Wells Fargo & Company MN boosted its stake in shares of Diplomat Pharmacy Inc (NYSE:DPLO) by 37.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 71,361 shares of the company’s stock after acquiring an additional 19,373 shares during the quarter. Wells Fargo & Company MN owned about 0.10% of Diplomat Pharmacy worth $1,478,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of DPLO. PNC Financial Services Group Inc. increased its stake in Diplomat Pharmacy by 46.7% during the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock worth $130,000 after acquiring an additional 2,794 shares during the last quarter. First Allied Advisory Services Inc. bought a new stake in Diplomat Pharmacy during the second quarter worth approximately $183,000. SG Americas Securities LLC bought a new stake in Diplomat Pharmacy during the third quarter worth approximately $191,000. BNP Paribas Arbitrage SA increased its stake in Diplomat Pharmacy by 57.6% during the second quarter. BNP Paribas Arbitrage SA now owns 13,992 shares of the company’s stock worth $207,000 after acquiring an additional 5,116 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Diplomat Pharmacy by 478.4% during the second quarter. Russell Investments Group Ltd. now owns 14,600 shares of the company’s stock worth $216,000 after acquiring an additional 12,076 shares during the last quarter. 72.21% of the stock is currently owned by institutional investors.
In other news, Director Jeffrey G. Park acquired 3,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The shares were bought at an average price of $15.46 per share, with a total value of $46,380.00. Following the completion of the purchase, the director now directly owns 7,640 shares in the company, valued at $118,114.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Joel Saban acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was purchased at an average cost of $15.24 per share, for a total transaction of $152,400.00. Following the purchase, the president now owns 12,000 shares of the company’s stock, valued at $182,880. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 15,000 shares of company stock worth $228,780. Insiders own 30.20% of the company’s stock.
Several equities research analysts have weighed in on DPLO shares. Deutsche Bank started coverage on Diplomat Pharmacy in a research note on Monday, December 4th. They set a “buy” rating and a $22.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and set a $23.75 price objective (up from $19.75) on shares of Diplomat Pharmacy in a research note on Wednesday, October 4th. BidaskClub raised Diplomat Pharmacy from a “hold” rating to a “buy” rating in a research note on Tuesday, September 26th. Mizuho set a $16.00 price objective on Diplomat Pharmacy and gave the stock a “hold” rating in a research note on Tuesday, October 24th. Finally, Leerink Swann boosted their price objective on Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 7th. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Diplomat Pharmacy currently has a consensus rating of “Buy” and a consensus target price of $20.94.
Diplomat Pharmacy Inc (NYSE:DPLO) opened at $25.22 on Friday. The company has a market capitalization of $1,736.98, a P/E ratio of 32.75, a PEG ratio of 3.93 and a beta of 0.62. Diplomat Pharmacy Inc has a 52 week low of $12.76 and a 52 week high of $26.37. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.82 and a current ratio of 1.34.
Diplomat Pharmacy (NYSE:DPLO) last released its earnings results on Monday, November 6th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.10. The firm had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The company’s quarterly revenue was down 4.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.21 earnings per share. sell-side analysts forecast that Diplomat Pharmacy Inc will post 0.85 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Wells Fargo & Company MN Has $1.48 Million Holdings in Diplomat Pharmacy Inc (DPLO)” was first posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.truebluetribune.com/2018/01/21/wells-fargo-company-mn-has-1-48-million-holdings-in-diplomat-pharmacy-inc-dplo.html.
Diplomat Pharmacy Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.